Program launch date: March 2020
The impact of migraine on quality of life and work-related activity is substantial but underestimated. However, migraine burden is difficult to assess both quantitatively and qualitatively due to the transient nature of migraine headaches and patient-reporting inconsistencies. The fact that headache disorders account for over 60% of neurological conditions and, according to recent analysis using disease-specific measures, reported in the Global Burden of Disease study, disability-adjusted life years (DALYs) run into the millions, suggests that there is a significant gap between knowledge and practice.

This new expert-led curriculum-based program covers the latest advances in migraine classification and acute management and will help you translate this knowledge into your clinical practice and improve your patients’ outcomes. The content has been published in phases, following a predetermined curriculum of learning activities which develop from the first stage, knowledge, moving onto competence and finally ending with performance.

The program is suitable for healthcare professionals worldwide who provide front-line care of patients with acute migraine, particularly primary care practitioners, internists and clinicians without a specialty in headache. It will also reinforce the existing knowledge of headache specialists.

Uwe Reuter discusses how to assess the efficacy of migraine treatment and when to change treatment plans.

Would you like to know more?

Register for a free account and you'll be the first to know when new content is available
Scroll to Top

Mario Peres

Professor, Psychiatry Institute, Sao Paulo University, Sao Paulo, Brazil

Mario Peres is a neurologist, who for the past 20 years has been dedicated to headache research, clinical practice, academic training and public awareness. He is currently President of ABRACES, a Brazilian headache advocacy association, Secretary of the Brazilian Headache Society, member of the Board of Trustees of the International Headache Society, and Professor at the Psychiatry Institute, University of Sao Paulo, Brazil.

Disclosures

Mario Peres discloses financial support/sponsorship from Lilly, Allergan, and Novartis in speaker fees, and consultation fees from Eurofarma, Lilly, Sanofi. Peres holds patent # BR2020170233532, from INPI – Instituto Nacional da Propriedade Industrial. Registered on 30/10/2017.

Uwe Reuter, Program Director

Professor of Neurology, Charité University Hospital, Berlin, Germany

Prof Dr Uwe Reuter is a neurologist and partner in the headache program at Charité Universitätsmedizin Berlin, Germany. Upon completing his residency training in Berlin he attended Harvard Medical School as a postdoctoral fellow. During his time in Boston he focused on basic research in primary headaches and migraine aura, and published several peer-reviewed publications in high impact journals. Uwe Reuter has been the principal investigator in numerous clinical trials and projects. He has published multiple manuscripts on CGRP and is the lead author in the first placebo controlled clinical trial with a monoclonal CGRP antibody for migraine prevention in patients, who previously did not respond to 2-4 conventional oral migraine preventatives.

He is a member of several national and international headache organizations and currently serves as a board member of the European Headache Federation.

Disclosures

Uwe Reuter discloses financial support and/or sponsorship from Allergan, Amgen, Novartis, Eli Lilly, TEVA, Medscape, and StreamedUp.

Sign up for eAlerts or take our quiz first and sign up at the end.

eAlerts